Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Galera Therapeutics
Biotech
Novartis R&D chief Jay Bradner departs—Chutes & Ladders
Novartis R&D chief Bradner to depart after seven years. Pfizer fills first chief marketing officer role. I-Mab sneaks two exec changes into earnings.
Max Bayer
,
Gabrielle Masson
Sep 2, 2022 9:30am
Galera shares rise over 100% as phase 3 flop deemed an error
Dec 14, 2021 3:30pm
Galera shares slide as radiotherapy complication drug fails
Oct 19, 2021 11:53am
Galera reels in $150M to test radiation side effect med in phase 3
Sep 19, 2018 11:10am
Poised for phase 3, Galera's GC4419 wards off radiation side effects
Aug 20, 2018 5:00am
